guest ::
| Home > Publications database > Update on Liquid Biopsy. > print |
| Home > Publications database > Update on Liquid Biopsy. > print |
| 001 | 302119 | ||
| 005 | 20250622021254.0 | ||
| 024 | 7 | _ | |a 10.1148/radiol.241030 |2 doi |
| 024 | 7 | _ | |a pmid:40525978 |2 pmid |
| 024 | 7 | _ | |a 0033-8419 |2 ISSN |
| 024 | 7 | _ | |a 1527-1315 |2 ISSN |
| 024 | 7 | _ | |a altmetric:178148899 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01251 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Mayerhoefer, Marius E |0 0000-0001-8786-8686 |b 0 |
| 245 | _ | _ | |a Update on Liquid Biopsy. |
| 260 | _ | _ | |a Oak Brook, Ill. |c 2025 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1750252884_1996 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Liquid biopsy helps detect cells and cell-derived metabolites, proteins, nucleic acids, and vesicles that are shed into body fluids by tumors. This diagnostic test requires only approximately 10 mL of blood or urine. It has received considerable attention as a minimally invasive tool for whole-body tumor interrogation for use in patients with cancer. It poses an attractive and potentially cost-effective alternative to invasive tissue sampling through tissue biopsies, especially serial assessments, such as for treatment response evaluation and mutations that occur during cancer treatment. Cell-free and circulating tumor DNA are the most frequently tested liquid biopsy analytes, and have shown promise for cancer screening, assessment of residual disease after treatment, and clinical outcome prediction and prognostication. Whereas liquid biopsy is less sensitive than imaging in early tumor stages, it is more specific and may help detect treatment response earlier than the Response Evaluation Criteria in Solid Tumors, or RECIST. Aimed primarily at radiologists, this review article provides an update on recent developments in the use of liquid biopsy, including findings from landmark clinical trials and U.S. regulatory approvals as companion diagnostic tests for clinical use, particularly in four malignancies: lymphoma, breast cancer, prostate cancer, and melanoma. Finally, current challenges for the clinical implementation of liquid biopsy are discussed. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Biomarkers, Tumor |2 NLM Chemicals |
| 650 | _ | 7 | |a Circulating Tumor DNA |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Liquid Biopsy: methods |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Biomarkers, Tumor: blood |2 MeSH |
| 650 | _ | 2 | |a Circulating Tumor DNA: blood |2 MeSH |
| 700 | 1 | _ | |a Kienzle, Andreas |0 P:(DE-He78)e584a92f41b005cab185e57fcc2a0957 |b 1 |u dkfz |
| 700 | 1 | _ | |a Woo, Sungmin |0 0000-0001-8459-8369 |b 2 |
| 700 | 1 | _ | |a Vargas, Hebert Alberto |0 0000-0003-1169-133X |b 3 |
| 773 | _ | _ | |a 10.1148/radiol.241030 |g Vol. 315, no. 3, p. e241030 |0 PERI:(DE-600)2010588-5 |n 3 |p e241030 |t Radiology |v 315 |y 2025 |x 0033-8419 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:302119 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e584a92f41b005cab185e57fcc2a0957 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOLOGY : 2022 |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-12 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b RADIOLOGY : 2022 |d 2024-12-12 |
| 920 | 1 | _ | |0 I:(DE-He78)D410-20160331 |k D410 |l Immuntherapie und -prävention |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D410-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|